Many of the most prominent publicly traded companies have familiar business models. They operate stores, provide financial services, produce and distribute energy, and drive innovation in technology, medicine and other fields. There are others, however, that operate unique, even bizarre, businesses, with few or even no publicly traded competitors.
Unusual companies operate niche businesses because they perceive opportunities for growth and ��in the long-run ��substantial profit. Oftentimes, this includes providing products and services in an underdeveloped sector of an established industry. For example, Clean Energy Fuels operates natural gas fueling stations throughout the United States and Canada, a unique business within the massive energy industry. GW Pharmaceuticals is the only publicly traded pharmaceutical company focusing on cannabinoid-based medications.
Best Bank Companies To Invest In 2015: Diageo plc(DEO)
Diageo plc engages in producing, distilling, brewing, bottling, packaging, distributing, developing, and marketing spirits, beer, and wine products worldwide. It offers a range of brands, including Johnnie Walker scotch whiskies, Smirnoff vodka and Smirnoff ready to drink products, Baileys Original Irish Cream liqueur, Crown Royal Canadian whisky, Captain Morgan rum and rum based products, Jose Cuervo tequila, JeB scotch whisky, Buchanan?s scotch whisky, Windsor Premier scotch whisky, Ketel One vodka, Ciroc vodka, Tanqueray gin, Bushmills Irish whiskey, and Guinness stout. The company also provides other spirits brands that comprise Gordon?s gin and vodka, Old Parr scotch whisky, Bell?s scotch whisky, The Classic Malts scotch whiskies, Seagram?s 7 Crown whiskey and Seagram?s VO whisky, Cacique rum, White Horse scotch whisky, Don Julio tequila, and Bundaberg rum. In addition, it offers beer under various brands, such as Malta Guinness non-alcoholic malt, Harp lager, Tu sker lager, Smithwick?s ale, Senator lager, and Red Stripe lager; and wine under a range of brands, including Blossom Hill, Sterling Vineyards, Beaulieu Vineyard, Navarro Correas, Acacia Vineyard, Rosenblum Cellars, Piat d?Or, Chalone Vineyard, and Santa Rita. Further, Diageo plc owns the distribution rights for the Jose Cuervo tequila brands in North America and internationally. The company was founded in 1886 and is based in London, the United Kingdom.
Advisors' Opinion:- [By Eric Volkman]
Diageo (NYSE: DEO ) can add another company to its portfolio of international assets. The company said it has gained control of United Spirits, an India-based whiskey distiller. This was effected by the purchase of a nearly 15% stake in the firm from a company controlled by Indian tycoon Vijay Mallya for 31.3 billion rupees ($520 million). That gives Diageo a direct stake of just more than 25% in United Assets. In combination with existing voting and governance arrangements with Mallya, it provides Diageo control of the company.
- [By Gordon Pape]
Meanwhile, London-based Diageo plc (DEO) controls many of the best-known liquor brands, including Johnnie Walker, Crown Royal, J&B, Bushmills, Captain Morgan, Tanqueray, Guinness, and a host of others.
Top Clean Energy Companies To Invest In 2014: Extreme Networks Inc.(EXTR)
Extreme Networks, Inc., together with its subsidiaries, develops and markets network infrastructure equipment and services to businesses, hospitals, schools, hotels, telecommunications companies, and government agencies. It offers Summit product family of stackable Ethernet switching systems that provide 10 megabit to 40 gigabit connection speeds, various physical presentations, and options to deliver power-over-Ethernet or unpowered standard Ethernet ports; and Black Diamond family of modular Ethernet switching systems, which deliver modular or chassis-based Ethernet connectivity solutions for enterprises, data centers, and service providers. The company also offers SummitWM family of wireless network controllers and associated Altitude access points to enable the deployment of nomadic and mobile converged network applications; and RidgeLine management software system that includes features tailored to data center, campus, and service provider management. It has strategic relationships with Motorola Inc., Netgear, Inc., Ericsson Enterprise AB, and Nokia Siemens Networks. The company sells its products through distributors, resellers, and field sales organizations. It operates in the United States, Canada, Mexico, Japan, Central America, Europe, the Middle East, Africa, South America, and the Asia Pacific. Extreme Networks, Inc. was founded in 1996 and is headquartered in Santa Clara, California.
Advisors' Opinion:- [By Jake L'Ecuyer]
Extreme Networks (NASDAQ: EXTR) shares tumbled 17.33 percent to $5.82 after the company reported downbeat Q2 results and issued a weak Q3 profit forecast.
- [By Jake L'Ecuyer]
Extreme Networks (NASDAQ: EXTR) shares tumbled 15.38 percent to $5.96 after the company reported downbeat Q2 results and issued a weak Q3 profit forecast.
Top Clean Energy Companies To Invest In 2014: MineralRite Corp (RITE)
MineralRite Corporation, formerly Royal Quantum Group Inc., incorporated on October 22, 1996, is a development-stage company. The Company is engaged in the acquisition, exploration and development of oil and gas and mineral properties. During the year ended December 31, 2009, the Company acquired a 36% interest in the drilling and development of the Gleason 4-16 well located in Oklahoma. In April 2013, it acquired the entire share capital of Goldfield International Inc.
The Company owns 100% interest in 1,540 acres that consist of 77 claims of prospective uranium property. The prospective uranium property is located adjacent to the Sheep Mountain Mine in Fremont County, Central Wyoming, approximately 90 miles southwest of Casper, Wyoming.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks MineralRite Corp (OTCMKTS: RITE), New China Global Inc (OTCMKTS: NCGI) and Metrospaces Inc (OTCMKTS: MSPC) have all been getting some extra attention lately in various investment newsletters thanks to a few paid promotions. Of course, there is nothing wrong with properly disclosed promotions or investor relations type of activities, but they can and often do backfire on unwary investors and traders alike. So how hot are these three small caps for investors? Here is a quick reality check:
Top Clean Energy Companies To Invest In 2014: Mylan Inc (MYL)
Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.
As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).
Generics Segment
The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.
The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.
In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.
In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.
Specialty Segment
The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.
Advisors' Opinion:- [By Sean Williams]
Veloci-Raptor time?
First up is Raptor Pharmaceuticals (NASDAQ: RPTP ) with Procysbi (previously known as RP-103), its oral delayed and extended-release medication to treat nephropathic cystinosis. In trials, Procysbi proved to be non-inferior to the only other FDA-approved treatment for nephropathic cystinosis, known as Cystagon from Mylan (NASDAQ: MYL ) . - [By Ben Eisen]
Mylan Inc. (MYL) �gained 3.6% after the pharmaceuticals company said it had settled litigation with Teva Pharmaceutical Industries (TEVA) over its Copaxone product.
- [By Keith Speights]
Heather Bresch
Heather Bresch was named CEO of Mylan (NASDAQ: MYL ) in 2012. At age 43, she is one of the youngest chief executives of a major corporation. Mylan ranks as the world's third-largest generic drugmaker and boasts a market cap of almost $12 billion with more than $7 billion in annual revenue.
No comments:
Post a Comment